News | January 18, 2013

Compact Proton Therapy Technology Achieves Milestone of Beam at Gantry Room Isocenter

ProTom Radiance 330

January 18, 2013 — Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330 proton therapy system at the McLaren Proton Therapy Center (MPTC) in Flint, Mich. This is the first time that ProTom has tested its compact system’s gantry beam optics design.

“Measuring high beam intensities at isocenter indicates well-functioning integration among various subsystems of the Radiance 330 necessary for clinical implementation,” said Vahagn Nazaryan, Ph.D., senior vice president of physics for ProTom. “We delivered beam through the gantry and nozzle in the first of three gantry treatment rooms as part of validation and verification of our technical design. We are pleased that the system performed as designed and quickly achieved a dose rate sufficient for standard clinical practice.”

“We are excited by the results of successful beam transport testing through our first gantry treatment room: these results were independently reproduced by our clinical physics team,” said Sung Park, Ph.D., chief physicist for McLaren Cancer Institute.

Earlier in the summer, ProTom installed a new custom-designed radiofrequency quadrupole (RFQ) proton linear accelerator (linac) injector from AccSys Technology Inc. This upgrade has significantly improved accelerated proton beam intensities. The RFQ upgrade resulted in an increase in injection intensity, yielding in excess of several times the number of protons per cycle accelerated in the synchrotron, with further tuning and optimization ongoing at McLaren.

“Both the ProTom and McLaren teams are to be commended for achieving this very significant result, which continues to validate that the system is performing as it was designed,” said ProTom CEO Stephen L. Spotts. “ProTom is focused on final validation and testing in order to secure all regulatory clearances necessary for clinical operation. It is my firm belief that our Radiance 330 system is not only the most advanced proton beam scanning system available but the most economical solution as well.“

The Radiance 330 proton therapy system has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the United States at this time.

For more information: www.protominternational.com, www.mclaren.org

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more